Natera, Inc. (NTRA) Dividend History

Company News

• Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape

  The report highlights the rapid advancements in the molecular diagnostics for cancer market, driven by trends like personalized medicine, pharmacogenomics, and liquid biopsy. It profiles over 140 companies and provides extensive data and forecasts to aid decision-making in this evolving global market.

  GlobeNewswire Inc.

  Featured Companies: A ABT EXAS GH ILMN QGEN TMO TXG
• Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings

  Stanley Druckenmiller's Duquesne Family Office investment vehicle has been concentrating its capital in a diverse mix of growth stocks and established businesses with substantial revenue opportunities, including Natera, Coupang, Coherent, Woodward, and Seagate Technology.

  The Motley Fool

  Featured Companies: COHR CPNG STX WWD
• Natera executive sells shares worth over $57k - Investing.com

  Natera's President and Chief Business Officer, John Fesko, has sold a portion of his company shares worth over $57,000 to meet tax obligations related to the vesting of restricted stock units. The transaction reflects changes in insider ownership of the company's stock.

  Investing.com
• Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

  Smart Beta ETF report for FBT

  Zacks Investment Research

  Featured Companies: BRKR FBT HALO IBB XBI
• Breaking Down Natera: 10 Analysts Share Their Views

  Natera (NASDAQ:NTRA) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 4 0 0 0 Last 30D 1 0 0 0 0 1M Ago 3 2 0 0 0 2M Ago 2 1 0 0 0 3M Ago 0 1 0 0 0 Analysts have set 12-month price targets for Natera, revealing an average target of $121.8, a high estimate of $142.00, and a low estimate of $100.00. Witnessing a positive shift, the current average has risen by 23.2% from the previous average price target of $98.86. Decoding Analyst Ratings: A Detailed Look The perception of Natera by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Tycho Peterson Jefferies Announces Buy $142.00 - David Westenberg Piper Sandler Raises Overweight $120.00 $110.00 Mark Massaro BTIG Raises Buy $125.00 $100.00 Kyle Mikson Canaccord Genuity Raises Buy $130.00 $100.00 Dan Brennan TD Cowen Raises Buy $137.00 $123.00 Catherine Ramsey Baird Raises Outperform $117.00 $99.00 Matthew Sykes Goldman Sachs Raises Buy $100.00 $90.00 Alexander Nowak Craig-Hallum Announces Buy $117.00 - Eve Burstein Bernstein Announces Outperform $120.00 - David Westenberg Piper Sandler Raises Overweight $110.00 $70.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Natera. This information provides a snapshot ...Full story available on Benzinga.com

  Benzinga